News
IPCIF
0.077
0.00%
0.000
Intellipharmaceutics GAAP EPS of -C$0.01, revenue of C$19.06M
Seekingalpha · 10/14 20:30
Intellipharmaceutics Announces Third Quarter 2022 Results
- Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral...
ACCESSWIRE · 10/14 20:15
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral s...
ACCESSWIRE · 08/16 12:00
Intellipharmaceutics International GAAP EPS of -$0.03
Intellipharmaceutics International press release (<a href="https://seekingalpha...
Seekingalpha · 07/21 21:15
Intellipharmaceutics Announces Second Quarter 2022 Results
Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral s...
ACCESSWIRE · 07/21 18:50
-- Earnings Flash (IPCIF) INTELLIPHARMACEUTICS INTERNATIONAL Reports Q1 Loss $-0.03
MT Newswires · 04/14 16:48
Intellipharmaceutics International reports Q1 results
Intellipharmaceutics International (IPCIF): Q1 GAAP EPS of -$0.04.Cash balance of $202.67K.Press Release
Seekingalpha · 04/14/2021 11:51
Intellipharmaceutics International reports FY results
Intellipharmaceutics International (IPCIF): FY GAAP EPS of -$0.14.Revenue of $1.4M (-59.8% Y/Y)Press Release
Seekingalpha · 03/01/2021 14:28
Intellipharmaceutics International reports Q3 results
Intellipharmaceutics International (IPCIF): Q3 GAAP EPS of $0.04.Revenue of $0.33M (-80.5% Y/Y)Press Release
Seekingalpha · 10/15/2020 21:24
FDA Ad Com thumbs down on Intellipharmaceutics' oxycodone ER
seekingalpha · 01/16/2020 03:02
Nektar Slumps As FDA Panel Gives Thumbs Down To Opioid Pain Drug; Program Shelved
Shares of midcap biopharma Nektar Therapeutics (NASDAQ: NKTR) are retreating sharply following a negative verdict handed down by FDA staffers for its opioid pain drug.
Benzinga · 01/15/2020 14:07
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.)
Benzinga · 01/15/2020 13:22
The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO
Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference.
Benzinga · 01/12/2020 22:05
Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
In a final push before the closing of the year, the FDA deemed it fit to clear even long pending ones, including Flexion Therapeutics Inc&#39;s (NASDAQ: FLXN) sNDA for the updation of the label for its osteoarthritis drug Zilretaa.
Benzinga · 01/01/2020 23:00
Stocks That Hit 52-Week Lows On Thursday
Before 10 a.m. ET on Thursday, 108 stocks hit new 52-week lows.
Benzinga · 10/17/2019 15:16
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday morning, 87 companies achieved new lows for the year.
Benzinga · 10/16/2019 14:55
Stocks That Hit 52-Week Lows On Tuesday
Before 10 am ET on Tuesday, 88 stocks hit new 52-week lows.
Benzinga · 10/15/2019 15:05
Intellipharmaceutics 6-K Shows Update On Purdue Litigation: Cases Have Been Stayed, Existing Trial Dates Vacated Amid Purdue Bankruptcy
Benzinga · 10/04/2019 12:13
More
Webull provides a variety of real-time IPCIF stock news. You can receive the latest news about Intellipharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About IPCIF
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.